|
陸、參考資料 1. Robert Allan Weinberg, The biology of cancer, Garland Science, 2007. 2. 行政院衛生署, http://www.doh.gov.tw/cht2006/index_populace.aspx, 2010. 3. WHO│Cancer, http://www.who.int/cancer/en/, 2010. 4. Andrew H. Ko, Malin Dollinger and Ernest H. Rosenbaum, Everyone's Guide to Cancer Therapy: How Cancer Is Diagnosed, Treated, and Managed Day to Day, Andrews McMeel Publishing, 2008. 5. Lauren Pecorino, Molecular biology of cancer: mechanisms, targets, and therapeutics, Oxford University Press, 2008. 6. Francis Giles, Srdan Verstovsek, Deborah Thomas, Stanton Gerson, Jorge Cortes, Stefan Faderl, Alessandra Ferrajoli, Farhad Ravandi, Steven Kornblau, Guillermo Garcia-Manero, Elias Jabbour, Susan O’Brien, Verena Karsten, Ann Cahill, Karen Yee, Maher Albitar, Mario Sznol and Hagop Kantarjian, Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combinedwith Cytarabine in Patients with Refractory Leukemia. Clin. cancer res. 2005, 11 (21), 7817-7824. 7. Yves Pommier, Elisabetta Leo, HongLiang Zhang and Christophe Marchand, DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. biol. 2010, 17 (5), 421-433. 8. Amir Kraitzer, Yoel Kloog, Roni Haklai and Mmital Zilberman, Composite fiber structures with antiproliferative agents exhibit advantageous drug delivery and cell growth inhibition in vitro. J. pharm. sci. 2010, DOI: 10.1002/jps.22238. 9. Paula Yurkanis Bruice, Organic Chemistry, Prentice Hall, 2006. 10. Ravi V. J. Chari, Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs. Acc. chem. res. 2008, 41 (1), 98-107. 11. N. V. Zhukov and S. A. Tjulandin, Targeted Therapy in the Treatment of Solid Tumors: Practice Contradicts Theory. Biochemistry mosc. 2008, 73 (5), 751-768. 59 12. National Cancer Institute-Dictionary of Cancer Terms, http://www.cancer.gov/ Templates/db_alpha.aspx?CdrID=270742, 2010. 13. Jed A Katzel, Michael P Fanucchi and Zujun Li, Recent advances of novel targeted therapy in non-small cell lung cancer. Journal of Hematology & Oncology, 2009, 2 (2). 14. Oliver Gautschi, Jim Heighway, Philip C. Mack, Phillip R. Purnell, Primo N. Lara, Jr. and David R. Gandara, Aurora Kinases as Anticancer Drug Targets. Clin. cancer res. 2008, 14 (6), 1639-1648. 15. David M. Glover, Mark H. Leibowitz, Doris A. McLean, and Huw Parry, Mutations in aurora Prevent Centrosome SeparationLeading to the Formation of Monopolar Spindles. Cell 1995, 81, 95-105. 16. Jingyan Fu, Minglei Bian, Qing Jiang, and Chuanmao Zhang, Roles of Aurora kinases in mitosis and tumorigenesis. Mol. cancer res. 2007, 5 (1), 1-10. 17. Kuo-Tai Yang, Shu-Kuei Li, Chih-Chieh Chang, Chieh-Ju C. Tang, Yi-Nan Lin, Sheng-Chung Lee, and Tang K. Tang, Aurora-C Kinase Deficiency Causes Cytokinesis Failure in Meiosis I and Production of Large Polyploid Oocytes in Mouse. Mol. biol. cell. 2010. 18. Chun Hei Antonio Cheung, Mohane Selvaraj Coumar, Hsing-Pang Hsieh, Jang-Yang Chang, Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin Investig Drugs 2009, 18 (4), 379-398. 19. David S. Boss, Jos H. Beijnen, Jan H.M. Schellens, Clinical experience with aurora kinase inhibitors: a review. Oncologist 2009, 14 (8), 780-793. 20. Nicholas Keen and Stephen Taylor, Aurora-kinase Inhibitors as Anticancer Agents. Nature Reviews. Cancer 2004, 4, 927-936. 21. Richard Bayliss, Teresa Sardon, Isabelle Vernos and Elena Conti, Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol. cell. 2003, 12 (4), 851-862. 22. Oliver Gautschi, Jim Heighway, Philip C. Mack, Phillip R. Purnell, Primo N. 60 Lara, Jr. and David R. Gandara, Aurora Kinases as Anticancer Drug Targets. Clin. cancer res. 2008, 14 (6), 1639-1648. 23. Régis Giet, Clotilde Petretti and Claude Prigent, Aurora kinases, aneuploidy and cancer, a coincidence or a real link? Trends in Cell Biology 2005, 15 (5), 241-250. 24. (a) Mohane Selvaraj Coumar, Chun Hei Antonio Cheung, Jang-Yang Chang and Hsing-Pang Hsieh, Advances in Aurora kinase inhibitor patents. Expert opin. ther. pat. 2009, 19 (3); (b) J.J.E.M. Kitzen, M. J. A. de Jonge, J. Verweij, Aurora kinase inhibitors. Critical Reviews in Oncology/Hematology 2009, 73 (2), 99-110; (c) John R. Pollard and Michael Mortimore, Discovery and Development of Aurora Kinase Inhibitors as Anticancer Agents. J. of med. chem. 2009, 52 (9), 2629–2651; (d) D. Bebbington et al., The discovery of the potent aurora inhibitor MK-0457 (VX-680). Bioorganic & Medicinal Chemistry Letters 2009, 19 (13), 3586-3592; (e) Mortlock et al., Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J. of med. chem. 2007, 50 (9), 2213-2224; (f) Yu-Hsiang Lo, Chi-Fong Lin, Shyh-Chyun Yang, Ming-Jung Wu, New Targets in Cell Cycle for New Antitumor Agents Development. CHEMISTRY (The Chinese Chemical Society, Taipei) 2008, 66 (4), 293-308. 25. H.-P. Hsieh et al., Identification, SAR Studies, and X-ray Co-crystallographic Analysis of a Novel Furanopyrimidine Aurora Kinase A Inhibitor. ChemMedChem : Chemistry Enabling Drug Discovery 2009, 5 (2), 255-267. 26. (a) Kathryn Calkins, The Rule of 5. BioCentury 2002, 10 (5), A1-A7; (b) Giulio Vistoli, Alessandro Pedretti and Bernard Testa, Assessing drug-likeness – what are we missing? Drug Discovery Today 2008, 13 (7-8), 285-294. 27. 蔡明宗, 國立清華大學博士論文, 2009. 28. Xiaoqi Chen, Weibo Wang, Chapter 32. The use of bioisosteric groups in lead optimization. Annu. rep. med. chem. 2003, 38, 333-346. 61 29. Edward H. Kerns and Li Di, Drug-like properties:Concepts, Structure Design and Methods, Elsevier Inc., 2008. 30. Ronald Borchardt, Edward Kerns, Michael Hageman, Dhrien Thakker and James Stevens, Optimizing the "Drug-Like" Properties of Leads in Drug Discovery, Springer Science, 2006. 31. Andreas Martin-Kohler, Jörg Widmer, Guido Bold, Thomas Meyer, Urs Séquin and Peter Traxlerb, Furo[2,3-d]pyrimidines and Oxazolo[5,4-d]pyrimidines as Inhibitors of Receptor Tyrosine Kinases (RTK). Helv. chim. acta. 2004, 87 (4), 956-975. 32. László Kürti and Barbara Czakó, Strategic Applications of Named Reactions in Organic Synthesis, Elsevier Inc., 2005. 33. (a) Singh et al., Identification of Kinase Inhibitors by an ATP Depletion Method. ASSAY and Drug Development Technologies 2004, 2 (2), 161-169; (b) Said Goueli, Brad Larson, Kevin Hsiao, Tracy Worzella, Aoife Gallagher and Eric Matthews, High-Throughput screening with quantitation of ATP concentration: A universal non-radioactive, homogenous assay for protein kinase. BMC Biotechnology 2004, 2 (10), 153-160. 34. (a) John A. Barltrop et al., 5-(3-carboxymethoxyphenyl)-2-(4,5-dimethylthiazoly) -3-(4-sulfophenyl)tetrazolium, inner salt (MTS) and related analogs of 3-(4,5 -dimethylthiazolyl)-2,5-diphenyltetrazolium bromide (MTT) reducing to purple watersoluble formazans as cell-viability indicators. Bioorg. Med. Chem. Lett. 1991, 1 (11), 611-614; (b) Gregor Malich, Boban Markovic and Chris Winder, The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. Toxicology 1997, 124 (3), 179-192; (c) CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay. Promega Part# TB169; (d) 林振瑋, 國立清華大學博士論文, 2010. 35. Francis A. Carey and Richard J. Sundberg, Advanced Organic Chemistry - Part B: Reactions and Synthesis (5th Edition), Springer, 2007. 62 36. Jacek Mlynarski, Joanna Jankowska and Bartosz Rakiel, Syntheses of chiral hybrid O,N-donor ligands for the investigation of lanthanide complex reactivities in direct aldol condensations. Tetrahedron, Asymmetry 2005, 16 (8), 1521-1526. 37. Atul Kumar, Pervez Ahmad, Ram Awatar Maurya, A.B. Singh and Arvind K. Srivastava, Novel 2-aryl-naphtho[1,2-d]oxazole derivatives as potential PTP-1B inhibitors showing antihyperglycemic activities. Eur. j. med. chem. 2009, 44 (1), 109-116. 38. Jeff B. Smaill, Gordon W. Rewcastle, Joseph A. Loo, Kenneth D. Greis, O. Helen Chan, Eric L. Reyner, Elke Lipka, H. D. Hollis Showalter, Patrick W. Vincent, William L. Elliott and William A. Denny, Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6 -acrylamides bearing additional solubilizing functions. J. of med. chem. 2000, 43 (7), 1380-1397. 39. Z. Tabarelli, D.B. Berlese, P.D. Sauzem, C.F. Mello and M.A. Rubin, Antinociceptive effects of Cremophor EL orally administered to mice. Brazilian Journal of Medical and Biological Research 2003, 36 (1), 119-123.
|